An innovative radiotherapy treatment will "eliminate the need for numerous hospital visits" and greatly improve the patient's quality of life, a health chief said.
Professor Carole Longson, director of health technology evaluation at Nice, said:
Unlike regular radiotherapy, with the Intrabeam Radiotherapy System only one dose is required.
This single dose is given at the same time as surgery, eliminating the need for numerous hospital visits.
Regular radiotherapy typically requires numerous doses over a three week period - although some people may receive it for longer - and is performed weeks or months after surgery or chemotherapy.
Whilst current evidence was not extensive, this type of radiotherapy was more convenient for patients and can improve a person's quality of life.
It's still a new treatment - so far only six centres in the UK have used the Intrabeam Radiotherapy System to treat early breast cancer.
Tens of thousands of breast cancer sufferers could soon be receiving an "innovative" type of radiotherapy treatment, it has emerged.
The National Institute for Health and Care excellence (Nice) gave intrabeam radiotherapy the seal of approval for use on the NHS.
The treatment involves administering a single dose of radiotherapy to patients during surgery.
A single dose of radiotherapy could be "more convenient" for patients, Nice said.
Intrabeam radiotherapy will be available to patients in the early stages of breast cancer.
In experiments on mice with the same type of HER2 positive breast cancer, scientists used an antibody drug to block activity of alpha v beta 6.
We found that simultaneously targeting alpha v beta 6 and HER2 in mice with tumours grown from human breast cancer cells greatly improved the effectiveness of Herceptin - even eliminating tumours that did not respond to Herceptin alone, which could have the potential to improve treatments for patients with these highly aggressive cancers.
Combining the antibody with the drug Herceptin, which targets the cancer-driving HER2 protein, completely eradicated the animals' tumours after six weeks of treatment. Using the antibody on its own reduced the size of tumours in the mice by 94.8%.
In comparison, treatment with Herceptin alone led to a 77.8% reduction.
Up to 70% of women with HER2-positive breast cancer either do not respond to Herceptin or develop resistance to the drug, leaving up to 7,000 women a year in the UK with limited treatment options.
Scientists found a molecule that helps tumours in an especially deadly form of breast cancer have grow and spread. The molecule, known as alpha v beta 6, could be used both to identify at-risk patients and develop new treatments, say scientists.
A study found high levels of alpha v beta 6 in 40% of tumours in women with HER2 positive breast cancer, a form of the disease that does not respond to conventional hormone therapy. These patients were twice as likely to die within five years of diagnosis as those with low levels of the molecule.
In experiments on mice with the same type of breast cancer, scientists used an antibody drug to block activity of alpha v beta 6. Combining the antibody with the drug Herceptin, which targets the cancer-driving HER2 protein, completely eradicated the animals' tumours after six weeks of treatment.
A simple blood test which could detect the early signs of breast cancer would allow a woman to "take control of her own risk", a medical expert said.
Dr Matthew Lam, senior research officer at the charity Breakthrough Breast Cancer, described the findings as "definitely promising".
This could mean that in the future a woman may be able to have a simple blood test to look for this DNA signature, and therefore know if she is at a higher risk of developing breast cancer.
If she does have this signature, she could then work with her doctor to explore the options available to help her take control of her own risk.
These could include lifestyle changes, tailored breast screening, risk-reducing drugs or surgery.
Data from a study into a potential blood test for breast cancer is "encouraging" as it would make early detection of the disease in all women much easier, a science chief has said.
Lead researcher on the study, Professor Martin Widschwendter, from University College London, said:
We identified an epigenetic signature in women with a mutated BRCA1 gene that was linked to increased cancer risk and lower survival rates.
Surprisingly, we found the same signature in large cohorts of women without the BRCA1 mutation and it was able to predict breast cancer risk several years before diagnosis.
The data is encouraging since it shows the potential of a blood-based epigenetic test to identify breast cancer risk in women without known predisposing genetic mutations.
A blood test for breast cancer could soon be available and offer an early warning system for all women, not just those with the BRCA genes, scientists said.
Experts found a molecular "switch" in blood samples which increase a women's chances of having breast cancer.
The marker is associated with the BRCA1 breast cancer gene but was also found in other breast cancer patients who went on to develop the disease.
Before this blood test there was no way of predicting the likelihood of breast cancer in someone if the disease did not run in their family.
Around 10% of breast cancers are caused by BRCA1 and BRCA2 gene variants inherited from parents, leaving 90% of cases unexplained.
Eating a lot of red meat in early adulthood could be associated with an increased risk of breast cancer, a new study suggests.
Having legumes - such as peas, beans and lentils - nuts, poultry, and fish instead of red meat could reduce the risk, they found.
Studies thus far have found no significant association between the consumption of red meat and breast cancer, but the team of US researchers said that most previous research has been based on diet during mid and later life.
Their study, published on bmj.com, looked at the dietary habits of 89,000 premenopausal women aged 26 to 43 in 1991.
Scientists behind the discovery that sufferers of aggressive breast cancer stand a better chance of survival if they have "killer" T-cells near their tumour said the finding was "key" to a better understanding of how to fight the disease.
Professor Peter Johnson,Cancer Research UK chief clinician, explained:
This research highlights the great strides we are making in understanding the complex interplay between cancer and the body's immune system.
These studies are key to informing how we are best able to treat patients in the clinic and to design better drugs that make the best use of the body's own defences.
The chances of beating aggressive breast cancer were raised for women who had "killer" T-cells near their tumour, a study has found.
The killer T-cells destroy cancerous cells by blasting them with toxic proteins and patients found to have them were 10% more likely to live for five years or more than a breast cancer sufferer without them.
The association was seen in women with non-hormone sensitive breast cancer and cancers marked by especially active HER2 genes.
Lead researcher Dr Raza Ali, a lecturer at the Cancer Research UK Cambridge Institute, explained: "This important insight could help doctors personalise a woman's treatment based on her immunological profile and also suggests new treatments should harness the immune system to fight cancer."